177 related articles for article (PubMed ID: 30879952)
1. EZH2 Inhibition in Ewing Sarcoma Upregulates G
Kailayangiri S; Altvater B; Lesch S; Balbach S; Göttlich C; Kühnemundt J; Mikesch JH; Schelhaas S; Jamitzky S; Meltzer J; Farwick N; Greune L; Fluegge M; Kerl K; Lode HN; Siebert N; Müller I; Walles H; Hartmann W; Rossig C
Mol Ther; 2019 May; 27(5):933-946. PubMed ID: 30879952
[TBL] [Abstract][Full Text] [Related]
2. Surface expression of the immunotherapeutic target G
Wiebel M; Kailayangiri S; Altvater B; Meltzer J; Grobe K; Kupich S; Rossig C
Cancer Rep (Hoboken); 2021 Oct; 4(5):e1394. PubMed ID: 33811471
[TBL] [Abstract][Full Text] [Related]
3. Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers.
Gargett T; Truong NTH; Gardam B; Yu W; Ebert LM; Johnson A; Yeo ECF; Wittwer NL; Tapia Rico G; Logan J; Sivaloganathan P; Collis M; Ruszkiewicz A; Brown MP
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38754916
[TBL] [Abstract][Full Text] [Related]
4. GD2-targeting therapy: a comparative analysis of approaches and promising directions.
Philippova J; Shevchenko J; Sennikov S
Front Immunol; 2024; 15():1371345. PubMed ID: 38558810
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers.
Fischer-Riepe L; Kailayangiri S; Zimmermann K; Pfeifer R; Aigner M; Altvater B; Kretschmann S; Völkl S; Hartley J; Dreger C; Petry K; Bosio A; von Döllen A; Hartmann W; Lode H; Görlich D; Mackensen A; Jungblut M; Schambach A; Abken H; Rossig C
Clin Cancer Res; 2024 Apr; ():OF1-OF14. PubMed ID: 38593230
[TBL] [Abstract][Full Text] [Related]
6. Ewing Sarcoma Single-cell Transcriptome Analysis Reveals Functionally Impaired Antigen-presenting Cells.
Visser LL; Bleijs M; Margaritis T; van de Wetering M; Holstege FCP; Clevers H
Cancer Res Commun; 2023 Oct; 3(10):2158-2169. PubMed ID: 37823774
[TBL] [Abstract][Full Text] [Related]
7. GD2-targeting CAR T-cell therapy for patients with GD2+ medulloblastoma.
Ciccone R; Quintarelli C; Camera A; Pezzella M; Caruso S; Manni S; Ottaviani A; Guercio M; Del Bufalo F; Quadraccia MC; Orlando D; Di Cecca S; Sinibaldi M; Aurigemma M; Iaffaldano L; Sarcinelli A; D' Amore ML; Ceccarelli M; Nazio F; Marabitti V; Giorda E; Pezzullo M; De Stefanis C; Carai A; Rossi S; Alaggio R; Del Baldo G; Becilli M; Mastronuzzi A; De Angelis B; Locatelli F
Clin Cancer Res; 2024 Mar; ():. PubMed ID: 38551501
[TBL] [Abstract][Full Text] [Related]
8. A miniaturized mode-of-action profiling platform enables high throughput characterization of the molecular and cellular dynamics of EZH2 inhibition.
Falkenstern L; Georgi V; Bunse S; Badock V; Husemann M; Roehn U; Stellfeld T; Fitzgerald M; Ferrara S; Stöckigt D; Stresemann C; Hartung IV; Fernández-Montalván A
Sci Rep; 2024 Jan; 14(1):1739. PubMed ID: 38242973
[TBL] [Abstract][Full Text] [Related]
9. Establishment of ganglioside GD2-expressing extranodal NK/T-cell lymphoma cell line with scRNA-seq analysis.
Sato S; Ishii M; Tachibana K; Furukawa Y; Toyota T; Kinoshita S; Azusawa Y; Ando J; Ando M
Exp Hematol; 2024 Feb; 130():104132. PubMed ID: 38029851
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic Hope on the Surface of Ewing Sarcoma.
Bailey KM
Clin Cancer Res; 2024 Mar; 30(5):934-936. PubMed ID: 38113033
[TBL] [Abstract][Full Text] [Related]
11. Emerging therapies in Ewing sarcoma.
Strauss SJ; Berlanga P; McCabe MG
Curr Opin Oncol; 2024 May; ():. PubMed ID: 38775200
[TBL] [Abstract][Full Text] [Related]
12. RNA Sequencing-Based Identification of Ganglioside GD2-Positive Cancer Phenotype.
Sorokin M; Kholodenko I; Kalinovsky D; Shamanskaya T; Doronin I; Konovalov D; Mironov A; Kuzmin D; Nikitin D; Deyev S; Buzdin A; Kholodenko R
Biomedicines; 2020 May; 8(6):. PubMed ID: 32486168
[TBL] [Abstract][Full Text] [Related]
13. Prospective investigation of drug resistance: an approach to understanding and optimizing the clinical benefit of targeted agents in Ewing sarcoma.
Bailey KM
Oncotarget; 2018 Dec; 9(99):37270-37271. PubMed ID: 30647860
[No Abstract] [Full Text] [Related]
14. Epigenetic Inhibition Puts Target Antigen in the Crosshairs of CAR T Cells.
Steffin DHM; Heslop HE
Mol Ther; 2019 May; 27(5):900-901. PubMed ID: 31005599
[No Abstract] [Full Text] [Related]
15. Overcoming Heterogeneity of Antigen Expression for Effective CAR T Cell Targeting of Cancers.
Kailayangiri S; Altvater B; Wiebel M; Jamitzky S; Rossig C
Cancers (Basel); 2020 Apr; 12(5):. PubMed ID: 32357417
[TBL] [Abstract][Full Text] [Related]
16. VEGFR2 as a target for CAR T cell therapy of Ewing sarcoma.
Englisch A; Altvater B; Kailayangiri S; Hartmann W; Rossig C
Pediatr Blood Cancer; 2020 Oct; 67(10):e28313. PubMed ID: 32729251
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic Therapy for Epithelioid Sarcoma.
Rothbart SB; Baylin SB
Cell; 2020 Apr; 181(2):211. PubMed ID: 32302562
[TBL] [Abstract][Full Text] [Related]
18. Targeting epigenetics in sarcomas through EZH2 inhibition.
Italiano A
J Hematol Oncol; 2020 Apr; 13(1):33. PubMed ID: 32264965
[TBL] [Abstract][Full Text] [Related]
19. B7H3-Directed Intraperitoneal Radioimmunotherapy With Radioiodinated Omburtamab for Desmoplastic Small Round Cell Tumor and Other Peritoneal Tumors: Results of a Phase I Study.
Modak S; Zanzonico P; Grkovski M; Slotkin EK; Carrasquillo JA; Lyashchenko SK; Lewis JS; Cheung IY; Heaton T; LaQuaglia MP; Cheung NV; Pandit-Taskar N
J Clin Oncol; 2020 Dec; 38(36):4283-4291. PubMed ID: 33119478
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
